AHR and psoriasis vulgaris: Tapinarof 1% cream is a first-in-class, non-steroidal aryl-hydrocarbon-receptor (AhR) agonist that received U.S. FDA approval in 2022 for adult plaque psoriasis and in 2024 for atopic dermatitis.3